GGrantIndex
← Leaderboards

Marco Pravetoni

Hennepin Healthcare Research Institute

Google Scholar ↗PubMed ↗ORCID ↗
$36,465,178
Attributed
$54,036,140
Total exposure
12
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $13M · FY2012–25
$20M$15M$10M$5M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$54,036,140 · 12

By mechanism

UG3$24,059,234 · 4
UH3$18,014,422 · 3
U01$9,732,531 · 2
R01$1,929,470 · 2
R21$300,483 · 1

Top collaborators

Others in their field

Top investigators on “Pharmaceutical Preparations”

Research focus

Pharmaceutical PreparationsAntibodiesOpioidVaccinesOxycodoneHeroinFentanylBuprenorphineBrainNaltrexoneRattusMethadoneSiteFormulationB-LymphocytesResearch Clinical TestingKeyhole Limpet HemocyaninSafetyToxicologyConjugate VaccinesHaptensLeadImmunogenicityCarrier Proteins

Grant awards (26)

Development of a monoclonal antibody to reverse overdose from fentanyl and its analogs: from manufacturing to clinical trials$3,410,308
UH3 · FY2025 · DA · contact PI
Development of computational and AI/ML tools to accelerate discovery of vaccines and antibodies against nitazenes and fentanyl analogs$637,128
R01 · FY2025 · DA · contact PI
Vaccines for fentanyl and its derivatives: A strategy to reduce illicit use and overdose$3,466,385
UH3 · FY2024 · DA · contact PI
Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components$3,569,552
UH3 · FY2023 · DA
Vaccines for fentanyl and its derivatives: A strategy to reduce illicit use and overdose$3,564,333
UH3 · FY2023 · DA · contact PI
Development of a monoclonal antibody to reverse overdose from fentanyl and its analogs: from manufacturing to clinical trials$8,267,350
UG3 · FY2022 · DA · contact PI
Vaccines for fentanyl and its derivatives: A strategy to reduce illicit use and overdose$4,003,844
UH3 · FY2022 · DA · contact PI
Antibody-based countermeasures against fentanyl and its analogues$774,408
U01 · FY2022 · DA · contact PI
Antibody-based countermeasures against fentanyl and its analogues$775,120
U01 · FY2021 · DA · contact PI
Vaccines for fentanyl and its derivatives: A strategy to reduce illicit use and overdose$1,704,238
UG3 · FY2020 · DA · contact PI
Novel nanovaccines against opioid use disorders$1,553,762
UG3 · FY2020 · DA
Antibody-based countermeasures against fentanyl and its analogues$813,791
U01 · FY2020 · DA · contact PI
Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components$3,788,472
UG3 · FY2019 · DA
Vaccines for fentanyl and its derivatives: A strategy to reduce illicit use and overdose$1,562,143
UG3 · FY2019 · DA · contact PI
Novel nanovaccines against opioid use disorders$1,537,430
UG3 · FY2019 · DA
Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components$1,524,758
UG3 · FY2019 · DA
Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine Components$4,121,081
UG3 · FY2018 · DA
Enhancing efficacy of vaccines for substance abuse through polymer-assisted delivery of immunomodulators$272,125
R01 · FY2018 · DA · contact PI
Vaccines for prescription opioid and heroin abuse$142,641
U01 · FY2018 · DA
Vaccines for prescription opioid and heroin abuse$2,393,499
U01 · FY2017 · DA
Enhancing efficacy of vaccines for substance abuse through polymer-assisted delivery of immunomodulators$581,016
R01 · FY2017 · DA · contact PI
Vaccines for prescription opioid and heroin abuse$2,365,673
U01 · FY2016 · DA
Enhancing efficacy of vaccines for substance abuse through polymer-assisted delivery of immunomodulators$439,201
R01 · FY2016 · DA · contact PI
Vaccines for prescription opioid and heroin abuse$2,467,399
U01 · FY2015 · DA
Early antigen-specific B cell responses as markers of oxycodone vaccine efficacy$146,139
R21 · FY2013 · DA · contact PI
Early antigen-specific B cell responses as markers of oxycodone vaccine efficacy$154,344
R21 · FY2012 · DA · contact PI